Steven A. Rosenberg
Surgery Branch
The Center for Cancer Research
United States of America
Biography
Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg developed the first effective immunotherapies and gene therapies for patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He was the first to successfully insert foreign genes into humans and his recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
Research Interest
Cancer Biology, Clinical Research, Immunology
Publications
-
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, et al. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 17: 4550-4557.
-
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, et al. (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 19: 747-752.
-
Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, et al. (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 344: 641-5.
-
Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, et al, (2016) Rosenberg SA T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 375: 2255-2262.
-
Tran E, Robbins PF, Rosenberg SA (2017) Final common pathway of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 18: 255-262.
